-
1
-
-
0017347943
-
Foundations of cost-effectiveness analysis for health and medical practices
-
doi:10.1056/NEJM197703312961304. PubMed: 402576
-
Weinstein MC, Stason WB, (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716-721. doi:10.1056/NEJM197703312961304. PubMed: 402576.
-
(1977)
N Engl J Med
, vol.296
, pp. 716-721
-
-
Weinstein, M.C.1
Stason, W.B.2
-
2
-
-
33644863151
-
Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems)
-
PubMed: 16673675
-
Hutton J, McGrath C, Frybourg JM, Tremblay M, Bramley-Harker E, et al. (2006) Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems). Int J Technol Assess Health Care. 22: 10-18. PubMed: 16673675.
-
(2006)
Int J Technol Assess Health Care
, vol.22
, pp. 10-18
-
-
Hutton, J.1
McGrath, C.2
Frybourg, J.M.3
Tremblay, M.4
Bramley-Harker, E.5
-
3
-
-
77953018037
-
A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006
-
doi:10.1177/0272989X09360066
-
Greenberg D, Rosen AB, Wacht O, Palmer J, Neumann PJ, (2010) A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. Med Decis Mak. 30: 320-327. doi:10.1177/0272989X09360066.
-
(2010)
Med Decis Mak
, vol.30
, pp. 320-327
-
-
Greenberg, D.1
Rosen, A.B.2
Wacht, O.3
Palmer, J.4
Neumann, P.J.5
-
4
-
-
33645505995
-
Bias in published cost effectiveness studies: systematic review
-
doi:10.1136/bmj.38737.607558.80. PubMed: 16495332
-
Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, et al. (2006) Bias in published cost effectiveness studies: systematic review. BMJ. 332: 699-703. doi:10.1136/bmj.38737.607558.80. PubMed: 16495332.
-
(2006)
BMJ
, vol.332
, pp. 699-703
-
-
Bell, C.M.1
Urbach, D.R.2
Ray, J.G.3
Bayoumi, A.4
Rosen, A.B.5
-
5
-
-
11844271509
-
Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study
-
doi:10.1136/bmj.38285.482350.82. PubMed: 15601681
-
Miners AH, Garau M, Fidan D, Fischer AJ, (2005) Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ. 330: 65. doi:10.1136/bmj.38285.482350.82. PubMed: 15601681.
-
(2005)
BMJ
, vol.330
, pp. 65
-
-
Miners, A.H.1
Garau, M.2
Fidan, D.3
Fischer, A.J.4
-
6
-
-
34247501840
-
Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups
-
PubMed: 17234022
-
Chauhan D, Miners AH, Fischer AJ, (2007) Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups. Int J Technol Assess Health Care. 23: 96-100. PubMed: 17234022.
-
(2007)
Int J Technol Assess Health Care
, vol.23
, pp. 96-100
-
-
Chauhan, D.1
Miners, A.H.2
Fischer, A.J.3
-
7
-
-
78049440721
-
Modeling in pharmacoeconomic studies: funding sources and outcomes
-
doi:10.1017/S0266462310000322. PubMed: 20584363
-
Garattini L, Koleva D, Casadei G, (2010) Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 26: 330-333. doi:10.1017/S0266462310000322. PubMed: 20584363.
-
(2010)
Int J Technol Assess Health Care
, vol.26
, pp. 330-333
-
-
Garattini, L.1
Koleva, D.2
Casadei, G.3
-
8
-
-
34347243202
-
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others
-
doi:10.1371/journal.pmed.0040184. PubMed: 17550302
-
Bero L, Oostvogel F, Bacchetti P, Lee K, (2007) Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLOS Med 4: e184. doi:10.1371/journal.pmed.0040184. PubMed: 17550302.
-
(2007)
PLOS Med
, vol.4
-
-
Bero, L.1
Oostvogel, F.2
Bacchetti, P.3
Lee, K.4
-
9
-
-
33646679623
-
Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005
-
doi:10.1001/jama.295.19.2270. PubMed: 16705108
-
Ridker PM, Torres J, (2006) Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA. 295: 2270-2274. doi:10.1001/jama.295.19.2270. PubMed: 16705108.
-
(2006)
JAMA
, vol.295
, pp. 2270-2274
-
-
Ridker, P.M.1
Torres, J.2
-
10
-
-
0043198131
-
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
-
doi:10.1001/jama.290.7.921. PubMed: 12928469
-
Als-Nielsen B, Chen W, Gluud C, Kjaergard LL, (2003) Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 290: 921-928. doi:10.1001/jama.290.7.921. PubMed: 12928469.
-
(2003)
JAMA
, vol.290
, pp. 921-928
-
-
Als-Nielsen, B.1
Chen, W.2
Gluud, C.3
Kjaergard, L.L.4
-
11
-
-
0037014942
-
Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ
-
doi:10.1136/bmj.325.7358.249. PubMed: 12153921
-
Kjaergard LL, Als-Nielsen B, (2002) Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 325: 249. doi:10.1136/bmj.325.7358.249. PubMed: 12153921.
-
(2002)
BMJ
, vol.325
, pp. 249
-
-
Kjaergard, L.L.1
Als-Nielsen, B.2
-
12
-
-
10744230594
-
Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials
-
PubMed: 14970094
-
Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, et al. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 170: 477-480. PubMed: 14970094.
-
(2004)
CMAJ
, vol.170
, pp. 477-480
-
-
Bhandari, M.1
Busse, J.W.2
Jackowski, D.3
Montori, V.M.4
Schünemann, H.5
-
13
-
-
0029018670
-
Manufacturing consensus, marketing truth: guidelines for economic evaluation
-
doi:10.7326/0003-4819-123-1-199507010-00010. PubMed: 7762917
-
Evans RG, (1995) Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med 123: 59-60. doi:10.7326/0003-4819-123-1-199507010-00010. PubMed: 7762917.
-
(1995)
Ann Intern Med
, vol.123
, pp. 59-60
-
-
Evans, R.G.1
-
14
-
-
49949104757
-
SLCO1B1 variants and statin-induced myopathy--a genomewide study
-
doi:10.1056/NEJMoa0801936. PubMed: 18650507, SEARCH Collaborative Group
-
SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman Let al. (2008) SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 359: 789-799. doi:10.1056/NEJMoa0801936. PubMed: 18650507.
-
(2008)
N Engl J Med
, vol.359
, pp. 789-799
-
-
Link, E.1
Parish, S.2
Armitage, J.3
Bowman, L.4
-
15
-
-
77549087054
-
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
-
doi:10.1016/S0140-6736(09)61965-6. PubMed: 20167359
-
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 375: 735-742. doi:10.1016/S0140-6736(09)61965-6. PubMed: 20167359.
-
(2010)
Lancet
, vol.375
, pp. 735-742
-
-
Sattar, N.1
Preiss, D.2
Murray, H.M.3
Welsh, P.4
Buckley, B.M.5
-
16
-
-
84864832599
-
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
-
Cholesterol Treatment Trialists' (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 380: 581-90.
-
(2012)
Lancet
, vol.380
, pp. 581-590
-
-
-
17
-
-
79960389336
-
Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era
-
doi:10.1161/CIR.0b013e318227720f. PubMed: 21709063
-
Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L, (2011) Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 124: 146-153. doi:10.1161/CIR.0b013e318227720f. PubMed: 21709063.
-
(2011)
Circulation
, vol.124
, pp. 146-153
-
-
Lazar, L.D.1
Pletcher, M.J.2
Coxson, P.G.3
Bibbins-Domingo, K.4
Goldman, L.5
-
18
-
-
79952052016
-
Statins for the primary prevention of cardiovascular disease
-
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, et al. (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev CD: pp. 004816.
-
(2011)
Cochrane Database Syst Rev CD
, pp. 004816
-
-
Taylor, F.1
Ward, K.2
Moore, T.H.3
Burke, M.4
Davey Smith, G.5
-
19
-
-
84859531777
-
Healthy men should not take statins
-
doi:10.1001/jama.2012.423. PubMed: 22496261
-
Redberg RF, Katz MH, (2012) Healthy men should not take statins. JAMA. 307: 1491-1492. doi:10.1001/jama.2012.423. PubMed: 22496261.
-
(2012)
JAMA
, vol.307
, pp. 1491-1492
-
-
Redberg, R.F.1
Katz, M.H.2
-
20
-
-
84869432250
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692
-
Newman DH, Saini V, Brody H, Brownlee S, Hoffman JR, et al. (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1814. doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692.
-
(2012)
Lancet
, vol.380
, pp. 1814
-
-
Newman, D.H.1
Saini, V.2
Brody, H.3
Brownlee, S.4
Hoffman, J.R.5
-
21
-
-
84869432250
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692
-
Donzelli A, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1814-1815. doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692.
-
(2012)
Lancet
, vol.380
, pp. 1814-1815
-
-
Donzelli, A.1
-
22
-
-
84869416480
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694
-
Battaggia A, Font M, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1815. doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694.
-
(2012)
Lancet
, vol.380
, pp. 1815
-
-
Battaggia, A.1
Font, M.2
-
23
-
-
84869416480
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694
-
Simpson WG, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1815-1816. doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694.
-
(2012)
Lancet
, vol.380
, pp. 1815-1816
-
-
Simpson, W.G.1
-
24
-
-
84869426457
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696
-
Mascitelli L, Goldstein MR, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1816. doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696.
-
(2012)
Lancet
, vol.380
, pp. 1816
-
-
Mascitelli, L.1
Goldstein, M.R.2
-
25
-
-
84869426457
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696
-
Ray KK, Redberg RF, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1816. doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696.
-
(2012)
Lancet
, vol.380
, pp. 1816
-
-
Ray, K.K.1
Redberg, R.F.2
-
26
-
-
84869410853
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62027-3. PubMed: 23177699
-
Zomer E, Owen AJ, Magliano DJ, Reid CM, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1817. doi:10.1016/S0140-6736(12)62027-3. PubMed: 23177699.
-
(2012)
Lancet
, vol.380
, pp. 1817
-
-
Zomer, E.1
Owen, A.J.2
Magliano, D.J.3
Reid, C.M.4
-
27
-
-
84869461894
-
Statins for people at low risk of cardiovascular disease
-
doi:10.1016/S0140-6736(12)62029-7. PubMed: 23177700
-
Wald N, Law M, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1818. doi:10.1016/S0140-6736(12)62029-7. PubMed: 23177700.
-
(2012)
Lancet
, vol.380
, pp. 1818
-
-
Wald, N.1
Law, M.2
-
28
-
-
68049122102
-
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
-
PRISMA Group
-
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6: e1000097.
-
(2009)
PLOS Med
, vol.6
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
29
-
-
84861757517
-
Financial relationships in economic analyses of targeted therapies in oncology
-
doi:10.1200/JCO.2011.38.6078. PubMed: 22430267
-
Valachis A, Polyzos NP, Nearchou A, Lind P, Mauri D, (2012) Financial relationships in economic analyses of targeted therapies in oncology. J Clin Oncol 30: 1316-1320. doi:10.1200/JCO.2011.38.6078. PubMed: 22430267.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1316-1320
-
-
Valachis, A.1
Polyzos, N.P.2
Nearchou, A.3
Lind, P.4
Mauri, D.5
-
30
-
-
80053373366
-
Financial conflicts of interest in economic analyses in oncology
-
PubMed: 21441858
-
Jang S, Chae YK, Majhail NS, (2011) Financial conflicts of interest in economic analyses in oncology. Am J Clin Oncol 34: 524-528. PubMed: 21441858.
-
(2011)
Am J Clin Oncol
, vol.34
, pp. 524-528
-
-
Jang, S.1
Chae, Y.K.2
Majhail, N.S.3
-
31
-
-
77953024444
-
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
-
doi:10.1007/s10549-010-0870-7. PubMed: 20352486
-
Jang S, Chae YK, Haddad T, Majhail NS, (2010) Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat 121: 273-279. doi:10.1007/s10549-010-0870-7. PubMed: 20352486.
-
(2010)
Breast Cancer Res Treat
, vol.121
, pp. 273-279
-
-
Jang, S.1
Chae, Y.K.2
Haddad, T.3
Majhail, N.S.4
-
32
-
-
0242659833
-
Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations
-
doi:10.1038/sj.bjc.6601308. PubMed: 14562007
-
Hartmann M, Knoth H, Schulz D, Knoth S, (2003) Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer. 89: 1405-1408. doi:10.1038/sj.bjc.6601308. PubMed: 14562007.
-
(2003)
Br J Cancer
, vol.89
, pp. 1405-1408
-
-
Hartmann, M.1
Knoth, H.2
Schulz, D.3
Knoth, S.4
-
33
-
-
0032724035
-
Evaluation of conflict of interest in economic analyses of new drugs used in oncology
-
doi:10.1001/jama.282.15.1453. PubMed: 10535436
-
Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL, (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 282: 1453-1457. doi:10.1001/jama.282.15.1453. PubMed: 10535436.
-
(1999)
JAMA
, vol.282
, pp. 1453-1457
-
-
Friedberg, M.1
Saffran, B.2
Stinson, T.J.3
Nelson, W.4
Bennett, C.L.5
-
34
-
-
4944235874
-
Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues
-
doi:10.1016/j.schres.2004.02.012. PubMed: 15474916
-
Basu A, (2004) Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res 71: 445-462. doi:10.1016/j.schres.2004.02.012. PubMed: 15474916.
-
(2004)
Schizophr Res
, vol.71
, pp. 445-462
-
-
Basu, A.1
-
35
-
-
0346366732
-
Quantitative analysis of sponsorship bias in economic studies of antidepressants
-
doi:10.1192/bjp.183.6.498. PubMed: 14645020
-
Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW, (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry. 183: 498-506. doi:10.1192/bjp.183.6.498. PubMed: 14645020.
-
(2003)
Br J Psychiatry
, vol.183
, pp. 498-506
-
-
Baker, C.B.1
Johnsrud, M.T.2
Crismon, M.L.3
Rosenheck, R.A.4
Woods, S.W.5
-
36
-
-
84859373020
-
Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review
-
doi:10.1177/0272989X11403834. PubMed: 21490308
-
Peura PK, Martikainen JA, Purmonen TT, Turunen JH, (2012) Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review. Med Decis Mak. 32: 237-245. doi:10.1177/0272989X11403834. PubMed: 21490308.
-
(2012)
Med Decis Mak
, vol.32
, pp. 237-245
-
-
Peura, P.K.1
Martikainen, J.A.2
Purmonen, T.T.3
Turunen, J.H.4
-
37
-
-
84857929499
-
Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review
-
doi:10.1186/cc11241. PubMed: 22405349
-
Thirugnanam S, Pinto R, Cook DJ, Geerts WH, Fowler RA, (2012) Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. Crit Care. 16: R43. doi:10.1186/cc11241. PubMed: 22405349.
-
(2012)
Crit Care
, vol.16
-
-
Thirugnanam, S.1
Pinto, R.2
Cook, D.J.3
Geerts, W.H.4
Fowler, R.A.5
-
38
-
-
33846534132
-
The cost-effectiveness of drug-eluting stents: a systematic review
-
PubMed: 17179219
-
Ligthart S, Vlemmix F, Dendukuri N, Brophy JM, (2007) The cost-effectiveness of drug-eluting stents: a systematic review. CMAJ. 176: 199-205. PubMed: 17179219.
-
(2007)
CMAJ
, vol.176
, pp. 199-205
-
-
Ligthart, S.1
Vlemmix, F.2
Dendukuri, N.3
Brophy, J.M.4
-
39
-
-
77949414359
-
Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis
-
doi:10.2165/11530530-000000000-00000. PubMed: 20222753
-
Fleurence RL, Spackman DE, Hollenbeak C, (2010) Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics. 28: 295-306. doi:10.2165/11530530-000000000-00000. PubMed: 20222753.
-
(2010)
Pharmacoeconomics
, vol.28
, pp. 295-306
-
-
Fleurence, R.L.1
Spackman, D.E.2
Hollenbeak, C.3
-
40
-
-
79953778308
-
Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test
-
PubMed: 21402681
-
Polyzos NP, Valachis A, Mauri D, Ioannidis JP, (2011) Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test. CMAJ. 183: E337-E343. PubMed: 21402681.
-
(2011)
CMAJ
, vol.183
-
-
Polyzos, N.P.1
Valachis, A.2
Mauri, D.3
Ioannidis, J.P.4
-
41
-
-
1642541979
-
Economic evaluations in Italy: a review of the literature
-
PubMed: 15095774
-
Garattini L, De Compadri P, Clemente R, Cornago D, (2003) Economic evaluations in Italy: a review of the literature. Int J Technol Assess Health Care. 19: 685-691. PubMed: 15095774.
-
(2003)
Int J Technol Assess Health Care
, vol.19
, pp. 685-691
-
-
Garattini, L.1
De Compadri, P.2
Clemente, R.3
Cornago, D.4
-
42
-
-
0031690809
-
The effectiveness of cost-effectiveness analysis in containing costs
-
doi:10.1046/j.1525-1497.1998.00201.x. PubMed: 9798812
-
Azimi NA, Welch HG, (1998) The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 13: 664-669. doi:10.1046/j.1525-1497.1998.00201.x. PubMed: 9798812.
-
(1998)
J Gen Intern Med
, vol.13
, pp. 664-669
-
-
Azimi, N.A.1
Welch, H.G.2
-
43
-
-
27344437362
-
Cost effectiveness of statins in coronary heart disease
-
doi:10.1136/jech.2005.034900. PubMed: 16234419
-
Franco OH, Peeters A, Looman CW, Bonneux L, (2005) Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health. 59: 927-933. doi:10.1136/jech.2005.034900. PubMed: 16234419.
-
(2005)
J Epidemiol Community Health
, vol.59
, pp. 927-933
-
-
Franco, O.H.1
Peeters, A.2
Looman, C.W.3
Bonneux, L.4
-
44
-
-
0025729633
-
Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
-
doi:10.1056/NEJM199105093241911. PubMed: 1901959
-
Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. (1991) Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 324: 1362-1365. doi:10.1056/NEJM199105093241911. PubMed: 1901959.
-
(1991)
N Engl J Med
, vol.324
, pp. 1362-1365
-
-
Hillman, A.L.1
Eisenberg, J.M.2
Pauly, M.V.3
Bloom, B.S.4
Glick, H.5
-
45
-
-
0031948222
-
Paying the piper for pharmacoeconomic studies
-
doi:10.1177/0272989X9801800205. PubMed: 9566464
-
Neumann PJ, (1998) Paying the piper for pharmacoeconomic studies. Med Decis Mak. 18: S23-S26. doi:10.1177/0272989X9801800205. PubMed: 9566464.
-
(1998)
Med Decis Mak
, vol.18
-
-
Neumann, P.J.1
-
46
-
-
4043076368
-
Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination
-
doi:10.1016/j.vaccine.2004.03.001. PubMed: 15308354
-
Beutels P, (2004) Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine. 22: 3312-3322. doi:10.1016/j.vaccine.2004.03.001. PubMed: 15308354.
-
(2004)
Vaccine
, vol.22
, pp. 3312-3322
-
-
Beutels, P.1
-
47
-
-
0344237248
-
Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result
-
doi:10.1093/rheumatology/keg456. PubMed: 14645870
-
Welsing PM, Severens JL, Laan RF, (2003) Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result. Rheumatology (Oxf). 42: 1574-1575. doi:10.1093/rheumatology/keg456. PubMed: 14645870.
-
(2003)
Rheumatology (Oxf)
, vol.42
, pp. 1574-1575
-
-
Welsing, P.M.1
Severens, J.L.2
Laan, R.F.3
-
48
-
-
33744988779
-
How NICE may be outflanked
-
doi:10.1136/bmj.332.7552.1268. PubMed: 16735342
-
Ferner RE, McDowell SE, (2006) How NICE may be outflanked. BMJ. 332: 1268-1271. doi:10.1136/bmj.332.7552.1268. PubMed: 16735342.
-
(2006)
BMJ
, vol.332
, pp. 1268-1271
-
-
Ferner, R.E.1
McDowell, S.E.2
-
49
-
-
0036311575
-
Being economical with the truth: how to make your idea appear cost effective
-
doi:10.1136/emj.19.4.301. PubMed: 12101135
-
Goodacre S, McCabe C, (2002) Being economical with the truth: how to make your idea appear cost effective. Emerg Med J 19: 301-304. doi:10.1136/emj.19.4.301. PubMed: 12101135.
-
(2002)
Emerg Med J
, vol.19
, pp. 301-304
-
-
Goodacre, S.1
McCabe, C.2
-
50
-
-
0343471474
-
Language bias in randomised controlled trials published in English and German
-
doi:10.1016/S0140-6736(97)02419-7. PubMed: 9251637
-
Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, et al. (1997) Language bias in randomised controlled trials published in English and German. Lancet. 350: 326-329. doi:10.1016/S0140-6736(97)02419-7. PubMed: 9251637.
-
(1997)
Lancet
, vol.350
, pp. 326-329
-
-
Egger, M.1
Zellweger-Zähner, T.2
Schneider, M.3
Junker, C.4
Lengeler, C.5
-
51
-
-
84857342101
-
Promoting transparency in pharmaceutical industry-sponsored research
-
doi:10.2105/AJPH.2011.300187. PubMed: 22095335
-
Ross JS, Gross CP, Krumholz HM, (2012) Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health. 102: 72-80. doi:10.2105/AJPH.2011.300187. PubMed: 22095335.
-
(2012)
Am J Public Health
, vol.102
, pp. 72-80
-
-
Ross, J.S.1
Gross, C.P.2
Krumholz, H.M.3
-
52
-
-
34848847826
-
Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?
-
doi:10.1371/journal.pmed.0040286. PubMed: 17896859
-
Sismondo S, (2007) Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLOS Med 4: e286. doi:10.1371/journal.pmed.0040286. PubMed: 17896859.
-
(2007)
PLOS Med
, vol.4
-
-
Sismondo, S.1
-
53
-
-
0028074701
-
The journal's policy on cost-effectiveness analyses
-
Kassirer JP, Angell M, (1994) The journal's policy on cost-effectiveness analyses. N Engl J Med. 331: 669-70.
-
(1994)
N Engl J Med
, vol.331
, pp. 669-670
-
-
Kassirer, J.P.1
Angell, M.2
-
54
-
-
0034716730
-
Pharmacoeconomic analyses: making them transparent, making them credible
-
doi:10.1001/jama.283.16.2158. PubMed: 10791510
-
Rennie D, Luft HS, (2000) Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 283: 2158-2160. doi:10.1001/jama.283.16.2158. PubMed: 10791510.
-
(2000)
JAMA
, vol.283
, pp. 2158-2160
-
-
Rennie, D.1
Luft, H.S.2
-
55
-
-
39449097300
-
Transparency of economic evaluations of health technologies
-
doi:10.2165/00019053-200826030-00002. PubMed: 18282013
-
Rovira J, (2008) Transparency of economic evaluations of health technologies. Pharmacoeconomics. 26: 181-183. doi:10.2165/00019053-200826030-00002. PubMed: 18282013.
-
(2008)
Pharmacoeconomics
, vol.26
, pp. 181-183
-
-
Rovira, J.1
-
56
-
-
84872621588
-
Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis
-
doi:10.1371/journal.pone.0038012. PubMed: 22666435
-
Catalá-López F, Alonso-Arroyo A, Aleixandre-Benavent R, Ridao M, Bolaños M, et al. (2012) Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis. PLOS ONE. 7: e38012. doi:10.1371/journal.pone.0038012. PubMed: 22666435.
-
(2012)
PLOS ONE
, vol.7
-
-
Catalá-López, F.1
Alonso-Arroyo, A.2
Aleixandre-Benavent, R.3
Ridao, M.4
Bolaños, M.5
-
57
-
-
79953800435
-
A glimpse into the black box of cost-effectiveness analyses
-
PubMed: 21402688
-
John-Baptiste AA, Bell C, (2011) A glimpse into the black box of cost-effectiveness analyses. CMAJ. 183: E307-E308. PubMed: 21402688.
-
(2011)
CMAJ
, vol.183
-
-
John-Baptiste, A.A.1
Bell, C.2
-
58
-
-
0034716729
-
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme
-
doi:10.1001/jama.283.16.2116. PubMed: 10791503
-
Hill SR, Mitchell AS, Henry DA, (2000) Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 283: 2116-2121. doi:10.1001/jama.283.16.2116. PubMed: 10791503.
-
(2000)
JAMA
, vol.283
, pp. 2116-2121
-
-
Hill, S.R.1
Mitchell, A.S.2
Henry, D.A.3
-
59
-
-
22944436125
-
Common methodological flaws in economic evaluations
-
PubMed: 16056003
-
Drummond M, Sculpher M, (2005) Common methodological flaws in economic evaluations. Med Care. 43: 5-14. PubMed: 16056003.
-
(2005)
Med Care
, vol.43
, pp. 5-14
-
-
Drummond, M.1
Sculpher, M.2
|